Summary of clinical trials from WUSTL (Washington University) and UMN (University of Minnesota) studying cohorts of patients with AML treated with adoptive haploidentical NK cell therapy with N-803 or IL-2 support and their outcome. In vivo expansion of donor NK and recipient CD8⁺ T-cell frequency at the indicated days after NK cell infusion (WUSTL cohort) (see Figure 1C and 1I in the article by Berrien-Elliott et al).¹ The low persistence of infused NK cells is related to recipient CD8⁺ T cell-mediated alloresponses induced by IL-15/N-803. Professional illustration by Somersault18:24.